文献速递类风湿关节炎

羟氯喹与类风湿关节炎患者呼吸道感染风险

Hydroxychloroquine and the risk of respiratory infections among RA patients.
PubMed 文献 · RMD Open · 2020-01-01

基于Corrona类风湿关节炎注册研究(2008年6月至2020年2月),比较生物制剂/靶向合成DMARDs初治患者中开始使用羟氯喹与其他csDMARDs者,发现任何呼吸道感染(上呼吸道感染、支气管炎、肺炎)发生率无差异,调整后HR=0.87(0.70-1.07)。

要点

  • 羟氯喹与其他csDMARDs相比,呼吸道感染风险无显著差异。
  • 调整后HR=0.87(0.70-1.07),匹配分析HR=0.90(0.70-1.17)。
  • 上呼吸道感染/支气管炎及严重呼吸道感染亚组结果相似。

核心结论

  • 在RA患者中,使用羟氯喹与其他非生物DMARDs相比,呼吸道感染风险相似。

研究设计与样本

  • 回顾性队列研究,基于Corrona RA注册(2008年6月至2020年2月),比较b/tsDMARDs初治的HCQ起始者与其他csDMARDs起始者及无HCQ者,采用时变调整Cox模型和倾向性匹配分析。

主要发现

  • 任何呼吸道感染(上呼吸道感染、支气管炎、肺炎)发生率在HCQ组与其他csDMARDs组间无差异,调整分析HR=0.87(0.70-1.07),匹配调整分析HR=0.90(0.70-1.17)。
  • 仅上呼吸道感染和支气管炎分析以及仅严重呼吸道感染分析结果相似。

临床怎么用

  • 在RA患者中处方羟氯喹时,无需因呼吸道感染风险顾虑而优先选择其他csDMARDs。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine the effect of hydroxychloroquine on the incidence of new respiratory infections in a large registry of rheumatoid arthritis (RA) patients compared with a matched cohort receiving other conventional disease-modifying antirheumatic drugs (csDMARDs). METHODS: We reviewed physician-reported infections including upper respiratory infections (URI), bronchitis and pneumonia in the Corrona RA registry from June 2008 to February 2020 with the goal of comparing infections in biologic/targeted synthetic (b/ts) DMARDs naive HCQ starts compared with starts of other csDMARDs and no HCQ. Patients on different interventions were compared using time-varying adjusted Cox models adjusting for age, sex, duration of RA, BMI, disease activity, smoking status, concurrent medications, season of the year, year of onset and history of serious infections, diabetes or cardiovascular disease (CVD). A secondary analysis in a set of propensity-matched starts were also compared adjusting for time-varying covariates. The analysis was repeated including URI and bronchitis only and also for serious respiratory infections only. RESULTS: No evidence of differences was found in the incidence of any respiratory infection (URI, bronchitis, pneumonia) in patients receiving HCQ compared with other csDMARDs: HR=0.87 (0.70 to1.07) in adjusted analyses and HR=0.90 (0.70 to 1.17) in adjusted matched analysis. Similar results were found in the analysis of URI and bronchitis only and for serious respiratory infections only. CONCLUSIONS: In patients with RA, the risk for respiratory infections was similar among patients using HCQ as compared to other non-biologic DMARDs.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Kremer JM, Reed G, Pappas DA, et al. Hydroxychloroquine and the risk of respiratory infections among RA patients. RMD Open. 2020. PMID: 33161375. doi:10.1136/rmdopen-2020-001389

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。